

CONTRACEPTION

INDEX TO VOLUME 27

AUTHOR INDEX

- Adams, R.J., 347, 363
Almonte, H., 311
Alsbach, G.P.J., 409
Alvarez, F., 123
Arreola, M., 311
Asch, R.H., 619
Balamceda, J.P., 619
Balogh, S.A., 63
Bardin, C.W., 627
Barkfeldt, J.O.A., 423
Bartlett, K.H., 497
Basnayake, S., 453, 465
Beck, L.R., 201
Bejar, E., 227, 239, 255, 267
Benson, H.D., 95
Berry, S.J., 347
Booth, M., 39
Bordy, M.J., 347
Borghi, M.R., 619
Bounds, W., 39
Brache, V., 123
Braun, J., 483
Breneman, W.R., 639
Burrow, G.N., 627
Bygdeman, M., 51, 141
Canfield, R.E., 627
Carlborg, L., 439
Casado, M.E., 1, 13, 27
Chatterji, D., 195
Chen, Q.Q., 391
Chow, A.W., 497
Christenssen, N.J., 51, 141
Cochran, R.C., 347, 363
Comite, F., 195
Córdova, M.S., 289
Coy, D.H., 619
Croxatto, H.B., 1, 13, 27, 281
Cutler, G.P., Jr., 195
Darney, K.J., Jr., 347
Decker, M.H., 195
Demey-Ponsart, E., 577
Desjardins, C., 347, 363, 383
Díaz, S., 1, 13, 27, 281
Diezfulusy, E., 177
Dinh, J., 483
Durán, E., 1, 13, 27
Duvivier, J., 577
Ehrlich, P.H., 627
Eneroeth, P., 329
Enríquez, R.G., 227, 239, 255, 267
Estrada, A.V., 227, 239, 255, 267
Etchegoyen, G., 591
Ewing, L.L., 347, 363, 383
Fajumi, J.O., 161
Faundes, A., 123
Fleetwood, L., 329
Forbes, A.D., 383
Fotherby, K., 153
Franchimont, P., 577
Franck, E.R., 409
Fraser, I., 531
Fu, W.O., 391
Gallegos, A.J., 211, 227, 239, 255, 267
Gallelli, J.F., 195
Galván, E., 591
Garza-Flores, J., 289

CONTRACEPTION

- Gasperd, U.J., 577
Gillain, D., 577
Girón, H., 227, 239, 255, 267
Goh, T.H., 75
Goldstein, M., 627
Gréen, 51, 141
Grunwell, J.F., 95
Guillebaud, 39
Hagenfeldt, K., 69
Hanafiah, M.J., 75
Haukkamaa, M., 571
Heine, M.W., 401
Herreros, C., 1, 13, 27
Ho, P.C., 339
Hong, S.S., 299, 605
Huber, A.C., 363
Hulting, A.-L., 69
Hutapea, H., 75
Jansen, R.P.S., 531
Jaszczak, S.E., 505
Johannisson, E., 177
Johansson, E.D.B., 123
Johnston, J.O., 95
Juez, G., 1, 13, 27
Karim, S.M.M., 75
Kato, K., 515
Kemp, P.L., 383
Kiriwat, O., 153
Kirton, K.T., 383
Kosonen, A., 85
Kurunmäki, H., 473
Kwak, H.M., 299
Lähteenmäki, P., 553
Lähteenmäki, P.L.A., 553
Landeros, J., 591
Landgren, B.-M., 177, 329
Lau, I., 521
Lee, W.M., 391
Liang, S.T., 339
Lim, L.S., 75
Lince, E., 289
Lobl, T.J., 383
Lopez, F., 311
Loriaux, D.L., 195
Lox, C.D., 401
Lozoya, X., 227, 239, 255, 267
Luukkainen, T., 571
Ma, H.K., 339
Macaulay, L.K., 131
McCarthy, T., 75
Mertzlufft, J., 521
Miller, P.C., 453, 465
Miranda, P., 1, 13, 27
Monarrez, G., 311
Nash, H.A., 123, 483
Navarro, C., 311
Niesvinsky, R., 619
O'Brien, F.B., 111
Odlin, V., 123, 423
Ortiz, E., 311
Pavez, M., 281
Pedrón, N., 255
Peralta, O., 1, 13, 27
Percival-Smith, R., 497
Perez-Palacios, G., 591
Pérez-Toral, M.C., 289
Perkin, G.W., 311
Petrow, V., 95
Piedras, J., 289
Pittaway, D.E., 431
Ponce-Monter, H., 227, 239, 255, 267
Poortman, J., 409

CONTRACEPTION

- Pope, C.E., 201
Pope, V.Z., 201
Ratnam, S.S., 75
Ratsula, K., 571
Rivera, R., 311
Robertson, D.N., 281, 483
Roche, P.C., 131
Rogers, S., 453, 465
Romus, M.A., 577
Roseman, T.J., 141
Rowlands, S., 39
Ruiz, R., 311
Ryu, K., 299, 605
Sairam, M.R., 515
Saksena, S., 521
Salvatierra, A.M., 1, 13, 27
Schally, A.V., 619
Sen, D.K., 75
Shaw, S.T., 131
Shumin, X., 177
Shu-rong, Z., 329
Simandjuntak, P., 75
Sinnathuray, 75
Sivanesaratnam, 75
Sivin, I., 483
Southam, L., 255
Spilman, C.H., 141
Stewart, W.C., 111
Strandberg, J.D., 363
Sturtevant, F.M. 111
Sun, N.C., 131
Tanaka, M.S., Jr., 131
Tang, G.W.K., 339
Thau, R.B., 627
Thiery, M., 85
Thijssen, J.H.H., 409
Toivonen, J., 553
Tsang, A.Y.F., 391
Tuttle, M.E., 141
Vesterqvist, O., 141
Victor, A., 423
Victor de Silva, S., 453, 465
Werner, S., 69
West, C.P., 553
White, M.J., 521
Wichmann, K., 571
Winterer, J., 195
Witkin, S.S., 627
Wolpert, E., 591
Wong, P.Y.D., 391
Yamamoto, Y., 627
Yu, H.K., 299
Zeller, F.J., 639



CONTRACEPTION

INDEX TO VOLUME 27

SUBJECT INDEX

- A-LH-RH ([N-Ac-D-Trp^{1,3},D-p-Cl-Phe²,D-Phe⁶,D-Ala¹⁰]-LH-RH)
Abortifacient effect, synthetic androstane derivatives (baboon), 201
Acceptability,
 comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
 norethisterone during breast-feeding, 563
Accidental pregnancy, randomised comparative evaluation of Cu-IUDs, 75
 $\text{1}\beta\text{-Acetoxy-17}\alpha\text{-ethinyl-17-hydroxy-18-methyl-4-osten-3-on}$, abortifacient effect (baboon), 201
 $\text{1}\beta\text{-17}\beta\text{-Acetoxy-18-methyl-4-osten-3-on}$, abortifacient effect (baboon), 201
Age, effect on incidence of pelvic inflammatory disease during Cu-7 clinical trials, III
Agonistic analogue of LH-RH, D-Trp⁶-LH-RH, 619
Aldosterone level,
 effect of ethynodiol + desogestrel monophasic, 577
 effect of ethynodiol + desogestrel sequential, 577
 effect of ethynodiol + levonorgestrel triphasic, 577
Androgenic/antiandrogenic activity, effect of RMI 12,936 (rat), 95
Androstane derivatives, abortifacient effect (baboon), 201
5-Androstan-3, 17-dione, effect on 17β -hydroxysteroid oxidoreductase activity (dog), 431
Anemia development after T Cu 220 insertion, predictive value of serum ferritin, 289
Anemic women,
 effects of ethynodiol + levonorgestrel on levels of hemoglobin, serum iron and iron binding capacity, 311
 effects of ethynodiol + levonorgestrel with ferrous fumarate on levels of hemoglobin, serum iron and iron binding capacity, 311
 effects of IUDs on levels of hemoglobin, serum iron and iron binding capacity, 311
Anovulatory luteal cycles (monkey), 505
Antagonistic activity, deglycosylated hCG (rat), 515
Antagonistic analogue of LH-RH, [N-Ac-D-Trp^{1,3},D-p-Cl-Phe²,D-Phe⁶,D-Ala¹⁰]-LH-RH, 619
Anti-hCG antiserum,
 antibody titers using the recommended standard assay, 627
 binding of hormones and subunits, 627

CONTRACEPTION

- characterization, 627
- determination of isoantibody class, 627
- Antifertility assay, RMI 12,936 (hamster), 95
- Antigonadotropic activity, effect of RMI 12,936 (rat), 95
- Antiprogesterational steroid, RMI 12,936, 95
- Antiuterotrophic/antiestrogenic activity, effect of RMI 12,936 (rat), 95
- Asialo hCG, effect on action of hCG (rat), 515
- bCH (baboon chorionic gonadotropin)
- bCH level, effect of synthetic androstane derivative (baboon), 201
- Bile lithogenic index,
 - effect of ethinyl estradiol + 1-norgestrel, 591
 - effect of norethisterone enanthate, 591
- Biliary lipid composition,
 - effect of ethinyl estradiol + 1-norgestrel, 591
 - effect of norethisterone enanthate, 591
- Biological activity of D-trp⁶-pro⁹-NET-LHRH, assessment for stability of solutions, 195
- Biological observations, zoapatic, 211
- Biological properties, zoapatic aqueous crude extract (guinea pig), 239
- Bleeding duration, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Bleeding patterns, effect of norethisterone during breast-feeding, 563
- Blood chemistry,
 - effect of testosterone + estradiol implant (monkey), 363, 383
 - effect of zoapatic aqueous crude extract (rat), 255
- Blood clotting, effect of testosterone + estradiol implant (monkey), 363
- Blood loss at vacuum aspiration,
 - comparison of different prostaglandin analogues and laminaria for preoperative cervical dilatation in late first trimester abortion, 51
 - pre-operative 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
- Blood pressure,
 - comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
 - effect of levonorgestrel-releasing capsules, 473
 - effect of Nova-T, 473
- Blood production rate of estradiol, effect of testosterone + estradiol implant (monkey) 347
- Blood production rate of testosterone, effect of testosterone + estradiol implant (monkey), 347

CONTRACEPTION

- Body weight,
 comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
 effect of levonorgestrel-releasing capsules, 473
 effect of lithosperm (chick), 639
 effect of lithosperm and propylthiouracil (chick), 639
 effect of Nova-T, 473
 effect of zoaplate aqueous crude extract (rat, dog), 255
- Botanical and ecological determinants, zoaplate, 227
- Breast-feeding,
 acceptability of norethisterone, 563
 effect of oral contraceptive regimens, 531
- Breast-feeding duration, effect of norethisterone, 563
- Cadmium-induced sterility, effect of zinc (rat), 521
- Capsules containing levonorgestrel,
 levonorgestrel plasma levels during continuous administration, 123
 release rate, 483
- Capsules releasing levonorgestrel, contraception after pregnancy termination, 473
- Cauda epididymides, effect of gossypol (rat), 391
- Cervical dilatation in late first trimester abortion, comparison of different
 prostaglandin analogues and laminaria, 51
- Cervical dilatation in termination of first trimester pregnancy, 16,16-dimethyl-trans-
 Δ^2 PGE₁ methyl ester, 339
- Cervical mucus changes, anovulatory luteal cycle (monkey), 505
- Cervical state at time of vacuum aspiration, pre-operative 16,16-dimethyl-trans-
 Δ^2 PGE₁ methyl ester, 339
- Characterization of a human anti-hCG antiserum, 627
- Cholesterol level,
 effect of injectable medroxyprogesterone acetate, 161
 effect of subdermal implant capsules containing levonorgestrel, 281
 effect of TCu 200, 281
- Chromatographic profile of D-trp⁶-pro⁹-N^{Et}-LHRH, assessment for stability of solutions,
 195
- Clinical chemistry tests,
 effect of subdermal implant capsules containing levonorgestrel, 281
 effect of TCu 200, 281
- Clinical data,
 first trimester pregnancy termination using polymeric controlled release vaginal
 delivery system containing (15S)15-methyl PGF_{2 α} methyl ester, 141

CONTRACEPTION

- second trimester pregnancy termination using polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF_{2 α} methyl ester, 141
Clinical factors influencing pill efficacy, 531
Clinical observations, zoapatle, 211
Clinical studies, zoapatle aqueous crude extract (rat, dog), 255
Clotting activity,
 interaction between ethanol and ethinyl estradiol (rat), 401
 interaction between ethanol and norethindrone (rat), 401
Comparative evaluation of copper 7, Multiload copper 250 and T copper-220C IUDs, 75
Complications after discharge from hospital, pre-operative 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
Compounds isolated from zoapatle, 211
Continuation,
 levonorgestrel-releasing capsules, 473
 Nova-T, 473
Continuation/withdrawal, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
Continuation rate,
 comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
 effect of vitamin supplementation during oral contraceptive use, 465
Contraceptive efficacy, testosterone + estradiol implant (monkey), 383
Contraceptive methods, prevalence rate of vaginal colonization of *E. coli*, 497
Contraceptive effects, RMI 12,936 (hamster), 95
Copper corrosion, MLCu250 and MLCu375 IUDs, 85
Copper T, fertility regulation in nursing women, 13
Corrosion and time of use, MLCu250 and MLCu375 IUDs, 85
Corrosion of filamentous intrauterine copper, MLCu250 and MLCu375, 85
Cortisol binding globulin level,
 effect of ethinylestradiol + desogestrel monophasic, 577
 effect of ethinylestradiol + desogestrel sequential, 577
 effect of ethinylestradiol + levonorgestrel triphasic, 577
Cortisol level,
 effect of ethinylestradiol + desogestrel monophasic, 577
 effect of ethinylestradiol + desogestrel sequential, 577
 effect of ethinylestradiol + levonorgestrel triphasic, 577
 effect of subdermal implant capsules containing levonorgestrel, 281
 effect of TCu 200, 281
Covered rods containing levonorgestrel,

CONTRACEPTION

- levonorgestrel plasma levels during continuous administration, 123
release rate, 483
- Cu-7,
incidence of pelvic inflammatory disease in clinical trials, 111
randomised comparative evaluation of Cu-IUDs, 75
- Cycle length,
anovulatory luteal cycle (monkey), 505
comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
effect of agonistic and antagonistic analogues of LH-RH (monkey), 619
- D-Trp⁶-LH-RH, effect on ovulation (monkey), 619
- D-trp⁶-pro⁹-NET-LHRH, assessment of stability of solutions, 195
- Danazol, side effects when used for postcoital contraception, 39
- Deglycosylated hCG, effect on ovulation (rat), 515
- 9-Deoxy-16,16-dimethyl-9-methylene PGE₂, preoperative cervical dilatation in late first trimester, 51
- Development of prolactinomas, influence of oral contraceptive steroids, 69
- 20 α -Dihydroprogesterone level, effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
- Dilatation of cervix in late first trimester abortion, comparison of different prostaglandin analogues and laminaria, 51
- Dilatation of cervix in termination of first trimester pregnancy, 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
- 16,16-Dimethyl-trans- Δ^2 PGE₁ methyl ester,
preoperative cervical dilatation in late first trimester, 51
pre-operative cervical dilatation in termination of first trimester pregnancy, 339
- Discontinuation, norethisterone during breast-feeding, 563
- Drug interactions, oral contraceptive regimens, 531
- Duration of breast-feeding, effect of norethisterone, 563
- Duration of use, effect on incidence of pelvic inflammatory disease during Cu-7 clinical trials, 111
- Dysmenorrhea,
effect of levonorgestrel-releasing capsules, 473
effect of Nova-T, 473
- E. coli vaginal colonization, significantly associated factors, 497
- Early first trimester pregnancy termination, polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF₂ α methyl ester, 141

CONTRACEPTION

- Ecological and botanical determinants, zoaplatle, 227
Effectiveness and interfering factors, oral contraceptive regimens, 531
Efficacy, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
Ejaculate volume, effect of testosterone + estradiol implant (monkey), 363
Electric pump, use in vacuum aspiration, 63
Endocrine properties, effect of RMI 12,936 (rat, hamster, rabbit), 95
Endometrial effect, progesterone released prematurely during proliferative phase, 177
Endometrial plasminogen activator activity, effect of IUDs, 131
Endometrium, subcellular distribution of estradiol and estrone during menstrual cycle, 409
Epididymis, effect of gossypol (rat), 391
Estradiol + testosterone,
 contraceptive efficacy (monkey), 383
 effect on testis function (monkey), 347
 somatic tissue responses (monkey), 363
Estradiol and estrone, subcellular distribution in endometrium and myometrium
 during menstrual cycle, 409
Estradiol blood production rate, effect of testosterone + estradiol implant (monkey), 347
Estradiol level,
 during menstrual cycle, 409
 during menstrual cycle of lactating women, 299
 effect of A-LH-RH (monkey), 619
 effect of D-Trp⁶-LH-RH (monkey), 619
 effect of ethinylestradiol + desogestrel monophasic, 577
 effect of ethinylestradiol + desogestrel sequential, 577
 effect of ethinylestradiol + levonorgestrel triphasic, 577
 effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
 effect of norethisterone enanthate, 553
 effect of Nova-T, 553
 effect of subdermal implant capsules containing levonorgestrel, 281
 effect of TCu 200, 281
 effect of testosterone + estradiol implant (monkey), 347
 effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
 normal cycle (monkey), 619
 normal menstruating women, 329

CONTRACEPTION

- testicular production after testosterone + estradiol implant (monkey), 347
- Estradiol metabolic clearance rate, effect of testosterone + estradiol implant (monkey), 347
- 4-Estrene-3,17-dione, effect on 17 β -hydroxysteroid oxidoreductase activity (dog), 431
- Estrogen determination, morning urine samples from normally menstruating women, 329
- Estrone level, during menstrual cycle, 409
- Ethanol and contraceptive steroids, interaction on clotting activity (rat), 401
- Ethinylestradiol + desogestrel monophasic, effect on plasma hormone levels, 577
- Ethinylestradiol + desogestrel sequential, effect on plasma hormone levels, 577
- Ethinyl estradiol + 1-norgestrel, effect on biliary lipid composition in Mexican women, 591
- Ethinyl estradiol + levonorgestrel, fertility regulation in nursing women, 1, 13, 27
- Ethinylestradiol + levonorgestrel triphasic, effect on plasma hormone levels, 577
- Ethinyl estradiol + norethindrone,
- comparison with mestranol + norethindrone in clinical trials, 453
 - effect of daily vitamin supplementation on side effects and discontinuation, 465
- Ethinyl estradiol + norgestrel,
- effect on gonadotropin responses to LH-RH in lactating women with regular menstrual cycles resumed, 605
 - effects on pituitary-ovarian function during menstrual cycle of lactating women, 299
- Ethinyl estradiol and ethanol, interaction on clotting activity (rat), 401
- Ethinyl oestradiol + levonorgestrel, comparison of monophasic and triphasic versions on acceptability, 439
- Ethyloestradiol + norgestrel, side effects when used for postcoital contraception, 39
- Ethyloestradiol + levonorgestrel, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Ethyloestradiol + levonorgestrel with ferrous fumarate, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Ethyloestradiol + norethisterone, pharmacokinetics after morning or evening administration, 153
- Ethyloestradiol level, after administration of ethyloestradiol + norethisterone, 153
- Expulsion, randomised comparative evaluation of Cu-IUDs, 75
- Factors significantly associated with vaginal carriage of E. coli, 497
- Ferritin level,
- effect of T Cu 220, 289
 - predictive value in anemia development after T Cu 220 insertion, 289
- Fertility,
- effect of cadmium (rat), 521

CONTRACEPTION

- effect of cadmium + zinc (rat), 521
- effect of testosterone + estradiol implant (monkey), 383
- Fertility regulation in nursing women,
 - copper T, 13
 - ethinyl estradiol + levonorgestrel, 1, 13, 27
- Filamentous intrauterine copper corrosion, MLCu250 and MLCu375, 85
- First treatment cycle, effectiveness of oral contraceptive regimens, 531
- First trimester pregnancy termination, pre-operative cervical dilatation using 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
- FSH (follicle stimulating hormone)
- FSH level,
 - during menstrual cycle of lactating women, 299
 - effect of ethinylestradiol + desogestrel monophasic, 577
 - effect of ethinylestradiol + desogestrel sequential, 577
 - effect of ethinylestradiol + levonorgestrel triphasic, 577
 - effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
 - effect of ethinylestradiol + norgestrel to response to LH-RH, 605
 - effect of ethinyl estradiol + norgestrel to response to LH-RH in lactating women with regular menstrual cycles resumed, 605
 - effect of norethisterone enanthate, 553
 - effect of Nova-T, 553
 - effect of testosterone + estradiol implant (monkey), 347
 - response to LH-RH, 605
 - response to LH-RH in lactating women with regular menstrual cycles resumed, 605
- Glucose level,
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Gonadotropin responses to LH-RH in lactating women with regular menstrual cycles resumed, effect of ethinyl estradiol + norgestrel, 605
- Gossypol,
 - clinical study of vaginal contraceptive efficacy, 571
 - effect on epididymis (rat), 391
- Growth of prolactinomas, influence of oral contraceptive steroids, 69
- Hand pump, use in vacuum aspiration, 63
- hCG (human choriongonadotropin)
- hCG antagonist, effect on ovulation (rat), 515

CONTRACEPTION

- hCG vaccine development, a proposed standard for laboratories, 627
hCH/LH level,
 effect of norethisterone enanthate, 553
 effect of Nova-T, 553
HDL (high density lipoprotein)
HDL-cholesterol,
 effect of subdermal implant capsules containing levonorgestrel, 281
 effect of TCu 200, 281
Hematological parameters, interaction between ethanol and contraceptive steroids
 (rat), 401
Hematological results, effect of zoaplate aqueous crude extract (rat), 255
Hematology, effect of testosterone + estradiol implant (monkey), 363, 383
Hemoglobin level,
 effect of ethynodiol + levonorgestrel in anemic women, 311
 effect of ethynodiol + levonorgestrel with ferrous fumarate in anemic
 women, 311
 effect of levonorgestrel-releasing capsules, 473
 effect of Nova-T, 473
 effect of T Cu 220, 289
 effects of IUDs in anemic women, 311
Hexanic extract of zoaplate aqueous crude extract, effect on uterine contractility
 (rat, guinea pig), 267
Homogeneous rods containing levonorgestrel, release rate, 483
Hormonal consequences of missed pills, oral contraceptive regimens, 531
Hormone changes during placebo week, oral contraceptive regimens, 531
17 β -Hydroxy-7 α -methyl-5-androstene-3-one (RMI 12,936), endocrine properties
 (rat, hamster, rabbit), 95
17-Hydroxyprogesterone level, effect of vaginal device releasing progesterone
 prematurely during proliferative phase, 177
17 β -Hydroxysteroid oxidoreductase activity,
 effect of different steroids on testosterone synthesis (dog), 431
 molecular characteristics necessary for competitive inhibition, 431
Inadvertent administration during very early pregnancy, oral contraceptive regimens, 531
Inadvertent pregnancies, oral contraceptive users, 531
Indomethacin, use in study of morphology and functions of anovulatory luteinized
 follicles (monkey), 505
Infant growth,

CONTRACEPTION

- effect of copper T in nursing women, 13
- effect of ethynodiol + levonorgestrel in nursing women, 1, 13, 27
- Inhibition of testosterone synthesis in testis (dog), 431
- Injectable contraceptive,
 - medroxyprogesterone acetate, 161
 - norethisterone enanthate, 553, 591
- Inorganic phosphorus level,
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Interfering factors and effectiveness, oral contraceptive regimens, 531
- Intermenstrual bleeding, comparison of ethynodiol + levonorgestrel monophasic and triphasic versions, 439
- Intracellular distribution,
 - estradiol and estrone in endometrium during menstrual cycle, 409
 - estradiol and estrone in myometrium during menstrual cycle, 409
- Intrauterine device (IUD),
 - copper T, 13
 - Cu7, 75, 311
 - effect on plasminogen activator activity in uterine tissue, 131
 - Lippes loop, 311
 - Lippes loop D, 131
 - MLCu250, 85
 - MLCu375, 85
 - Multiload Cu250, 75
 - Nova-T, 473, 553
 - Progestasert, 311
 - Saf-T-Coil, 131
 - TCu 200, 281
 - TCu 220, 289
 - TCU-220C, 75, 311
- Ionic content, different aqueous zoapatic crude extracts, 239
- IPAS Modified Gynecologic Syringe, use in vacuum aspiration, 63
- Iron binding capacity,
 - effect of ethynodiol + levonorgestrel in anemic women, 311
 - effect of ethynodiol + levonorgestrel with ferrous fumarate in anemic women, 311
 - effects of IUDs in anemic women, 311
- IUD (intrauterine device)

CONTRACEPTION

- Kauradienoic acid ((-)-kaura-9(11),16-dien-19-oic acid),
effect on uterine contractility (rat, guinea pig), 267
obtained from hexanic extract of zoapatle leaves, 267
- Lactating women, effect of ethinyl estradiol + norgestrel on pituitary-ovarian
function during menstrual cycle, 299
- Lactating women with regular menstrual cycles resumed, effect of ethinyl
estradiol + norgestrel on gonadotropin responses to LH-RH, 605
- Lactation,
effect of copper T, 13
effect of ethinyl estradiol + levonorgestrel, 1, 13, 27
- Laminaria tent, preoperative cervical dilatation in late first trimester, 51
- Late first trimester abortion, comparison of different prostaglandin analogues and
laminaria for preoperative dilatation of cervix, 51
- LDL (low density lipoprotein)
- LDL-cholesterol,
effect of subdermal implant capsules containing levonorgestrel, 281
effect of TCu 200, 281
- Levonorgestrel level,
during use of capsules containing levonorgestrel, 123
during use of covered rods containing levonorgestrel, 123
influence of period from application of tourniquet to withdrawal of blood, 123
sample taken from arm with implants vs. other arm, 123
- Levonorgestrel release rates, capsules, homogeneous rods and covered rods, 483
- Levonorgestrel-containing capsules,
effect on clinical chemistry, 281
levonorgestrel plasma levels during continuous administration, 123
release rate, 483
- Levonorgestrel-containing covered rods,
levonorgestrel plasma levels during continuous administration, 123
release rate, 483
- Levonorgestrel-containing homogeneous rods, release rate, 483
- Levonorgestrel-releasing capsules, contraception after pregnancy termination, 473
- LH (luteinizing hormone or immunoreactive lutropin)
LH level,
during menstrual cycle of lactating women, 299
effect of A-LH-RH (monkey), 619

CONTRACEPTION

- effect of D-Trp⁶-LH-RH (monkey), 619
- effect of ethinylestradiol + desogestrel monophasic, 577
- effect of ethinylestradiol + desogestrel sequential, 577
- effect of ethinylestradiol + levonorgestrel triphasic, 577
- effect of ethynodiol diacetate + norethindrone acetate during menstrual cycle of lactating women, 299
- effect of ethynodiol diacetate + norethindrone acetate to response to LH-RH, 605
- effect of ethynodiol diacetate + norethindrone acetate to response to LH-RH in lactating women with regular menstrual cycles resumed, 605
- effect of testosterone + estradiol implant (monkey), 347
- effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
- normal cycle (monkey), 619
- normal menstruating women, 329
- response to LH-RH, 605
- response to LH-RH in lactating women with regular menstrual cycles resumed, 605
- LH/hCG level,
 - effect of norethisterone enanthate, 553
 - effect of Nova-T, 553
- LHRH (luteinizing hormone releasing hormone)
- LHRH analogue,
 - D-Trp⁶-LH-RH, 619
 - D-trp⁶-pro⁹-NEt-LHRH, 195
 - [N-Ac-D-Trp^{1,3},D-p-Cl-Phe²,D-Phe⁶,D-Ala¹⁰]-LH-RH, 619
- LH-RH stimulation, effect of ethynodiol diacetate + norethindrone acetate to gonadotropin responses in lactating women with regular menstrual cycles resumed, 605
- Lipids and side effects, effect of medroxyprogesterone acetate in Nigerian women, 161
- Lipoprotein pattern,
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Lippes loop, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Lippes loop D, effect on plasminogen activator activity in uterine tissue, 131
- Lithosperm (*Lithospermum ruderale* plant extract)
 - Lithospermum ruderale* plant extract (lithosperm), effect on thyroidal ³²P uptake (chick), 639

CONTRACEPTION

- Luteal phase length,
 - anovulatory luteal cycle (monkey), 505
 - effect of agonistic and antagonist analogues of LH-RH (monkey), 619
- Luteinization of unruptured follicles, anovulatory luteal cycle (monkey), 505
- Luteinized anovulatory follicle (monkey), 505
- Mechanism of action,
 - estrogen-progestogen combinations, 531
 - progestogen-only formulations, 531
- Medroxyprogesterone acetate, effect on blood lipids and side effects in Nigerian women, 161
- Menses induction, polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF₂_α methyl ester, 141
- Menstrual bleeding, effect of norethisterone during breast-feeding, 563
- Menstrual cycle,
 - effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
 - subcellular distribution of estradiol and estrone in endometrium and myometrium, 409
- Menstrual cycle of lactating women, effect of ethinyl estradiol + norgestrel on pituitary-ovarian function, 299
- Menstrual disturbances,
 - levonorgestrel-releasing capsules, 473
 - Nova-T, 473
- Menstrual flow,
 - effect of levonorgestrel-releasing capsules, 473
 - effect of Nova-T, 473
- Mestranol + norethindrone,
 - comparison with ethinyl estradiol + norethindrone in clinical trials, 453
 - effect of daily vitamin supplementation on side effects and discontinuation, 465
- Metabolic clearance rate of estradiol, effect of testosterone + estradiol implant (monkey), 347
- Metabolic clearance rate of testosterone, effect of testosterone + estradiol implant (monkey), 347
- 15-Methyl-PGF₂_α methyl ester, preoperative cervical dilatation in late first trimester, 51
- Mexican women, effects of synthetic steroid contraceptives on biliary lipid composition, 591
- Missed oral contraceptive pills,

CONTRACEPTION

- hormonal consequences, 531
- risk of pregnancy, 531
- Morning or evening administration, pharmacokinetics of ethynodiol + norethisterone, 153
- Morning urine samples from normally menstruating women, determination of total urinary estrogens, 329
- Morphology of luteinized anovulatory follicle (monkey), 505
- Motility initiation of spermatozoa, effect of gossypol on epididymis (rat), 391
- Multiload Cu250, randomized comparative evaluation of Cu-IUDs, 75
- Myometrium, subcellular distribution of estradiol and estrone during menstrual cycle, 409
- [N-Ac-D-Trp^{1,3},D-p-Cl-Phe²,D-Phe⁶,D-Ala¹⁰]-LH-RH (A-LH-RH), effect on ovulation (monkey), 619
- Naproxen-sodium, use in study of morphology and functions of anovulatory luteinized follicles (monkey), 505
- Nausea, danazol compared with ethynodiol + norgestrel when used for postcoital contraception, 39
- Nigerian women, effect of medroxyprogesterone acetate on blood lipids and side effects, 161
- Norethindrone and ethanol, interaction on clotting activity (rat), 401
- Norethisterone, acceptability during breast-feeding, 563
- Norethisterone and phenytoin, interaction (monkey) 423
- Norethisterone enanthate,
 - effect on biliary lipid composition in Mexican women, 591
 - postabortal contraception, 553
- Norethisterone level,
 - after administration of ethynodiol + norethisterone, 153
 - after postabortal norethisterone enanthate, 553
 - effect of phenytoin (monkey), 423
- Nova-T,
 - contraception after pregnancy termination, 473
 - postabortal contraception, 553
- Nulliparous women, incidence of pelvic inflammatory disease during Cu-7 clinical trials, 111
- Nursing women,
 - influence of copper T, 13
 - influence of ethynodiol + levonorgestrel on lactation and infant growth, 1, 13, 27

CONTRACEPTION

- Onset of post-treatment period, danazol compared with ethinyloestradiol + norgestrel when used for postcoital contraception, 39
- Operative complications at vacuum aspiration, pre-operative 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
- Oral contraceptive,
- drug interactions, 531
 - effectiveness and interfering factors, 531
 - ethinylestradiol + desogestrel monophasic, 577
 - ethinylestradiol + desogestrel sequential, 577
 - ethinyl estradiol + 1-norgestrel, 591
 - ethinyl estradiol + levonorgestrel, 1, 13, 27
 - ethinylestradiol + levonorgestrel triphasic, 577
 - ethinyl estradiol + norethindrone with ferrous fumarate, 453, 465
 - ethinyl estradiol + norgestrel, 299, 605
 - ethinyl oestradiol + levonorgestrel, 439
 - ethinyl oestradiol + levonorgestrel triphasic, 439
 - ethynodiol + levonorgestrel, 311
 - ethynodiol + levonorgestrel with ferrous fumarate, 311
 - ethynodiol + norethisterone, 153
 - mechanism of action, 531
 - mestranol + norethindrone with ferrous fumarate, 453, 465
 - norethisterone, 563
- Oral contraceptive steroids, influence on development or growth of prolactinomas, 69
- Oral contraceptive users, inadvertent pregnancies, 531
- Organ weight assay, RMI 12, 936 (rat), 95
- Outcome variables, vacuum aspiration with IPAS Modified Gynecologic Syringe compared with electric pump and standard hand pump, 63
- Ovarian cycle, plasminogen activator activity during different phases, 131
- Ovarian effect, progesterone released prematurely during proliferative phase, 177
- Ovulation,
- anovulatory luteal cycle (monkey), 505
 - effect of agonistic and antagonistic analogues of LH-RH (monkey), 619
 - effect of hCG antagonist (rat), 515
- Oxytocin, uterine response (guinea pig), 239
- Parous women, incidence of pelvic inflammatory disease during Cu-7 clinical trials, III
- Pelvic inflammatory disease, incidence in clinical trials with Cu-7, III
- PG (prostaglandin)
- Pharmacokinetic parameters for ethynodiol, after morning or evening administration

CONTRACEPTION

- of ethynodiol + norethisterone, 153
- Pharmacokinetic parameters for norethisterone, after morning or evening administration of ethynodiol + norethisterone, 153
- Pharmacokinetics after morning or evening administration, ethynodiol + norethisterone, 153
- 16-Phenoxy- ω -17,18,19,20-tetranor PGE₂ methyl sulfonyl amide, preoperative cervical dilatation in late first trimester, 51
- Phenytoin and norethisterone, interaction (monkey), 423
- Phospholipids level, effect of injectable medroxyprogesterone acetate, 161
- Pill dosage and unusual pill regimens, effectiveness of oral contraceptive regimens, 531
- Pituitary, ovarian and endometrial effects, progesterone released prematurely during proliferative phase, 177
- Pituitary-ovarian function during menstrual cycle of lactating women, effect of ethynodiol + norgestrel, 299
- Plasma renin activity,
 - effect of ethynodiol + desogestrel monophasic, 577
 - effect of ethynodiol + desogestrel sequential, 577
 - effect of ethynodiol + levonorgestrel triphasic, 577
- Plasminogen activator, changes in uterine tissue induced by IUDs, 131
- Platelet count, interaction between ethanol and contraceptive steroids (rat), 401
- Postabortal contraception,
 - norethisterone enanthate, 553
 - Nova-T, 553
- Postcoital contraceptive,
 - danazol, 39
 - ethynodiol + norgestrel, 39
- Postcoital test, effect of gossypol, 571
- Potassium concentration, effect of gossypol on epididymis (rat), 391
- Predictive value of serum ferritin in anemia development after T Cu 220 insertion, 289
- Pregnancy,
 - effect of synthetic androstane derivatives (baboon), 201
 - inadvertent administration of oral contraceptives, 531
- Pregnancy termination,
 - immediate contraception with levonorgestrel-releasing capsules, 473
 - immediate contraception with Nova-T, 473

CONTRACEPTION

- Preoperative cervical dilatation in late first trimester, comparison of different prostaglandin analogues and laminaria, 51
- Pre-operative cervical dilatation in termination of first trimester pregnancy, 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
- Progestasert, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Progesterational/antiprogestational activity, effect on RMI 12,936 (rat, rabbit), 95
- Progesterone level,
- anovulatory luteal cycle (monkey), 505
 - during menstrual cycle of lactating women, 299
 - effect of A-LH-RH (monkey), 619
 - effect of D-Trp⁶-LH-RH (monkey), 619
 - effect of ethinylestradiol + desogestrel monophasic, 577
 - effect of ethinylestradiol + desogestrel sequential, 577
 - effect of ethinylestradiol + levonorgestrel triphasic, 577
 - effect of ethynodiol diacetate + norgestrel during menstrual cycle of lactating women, 299
 - effect of norethisterone enanthate, 553
 - effect of Nova-T, 553
 - effect of synthetic androstane derivatives (baboon), 201
 - effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
 - normal cycle (monkey), 619
- Progesterone released prematurely during proliferative phase, pituitary, ovarian and endometrial effects, 177
- Prolactin level,
- during menstrual cycle, 299, 605
 - during menstrual cycle of lactating women, 299, 605
 - effect of ethinylestradiol + desogestrel monophasic, 577
 - effect of ethinylestradiol + desogestrel sequential, 577
 - effect of ethinylestradiol + levonorgestrel triphasic, 577
 - effect of ethynodiol diacetate + norgestrel, 605
 - effect of ethynodiol diacetate + norgestrel during menstrual cycle of lactating women, 299
 - effect of ethynodiol diacetate + norgestrel in lactating women with regular menstrual cycles resumed, 605

CONTRACEPTION

- Prolactinomas, influence of oral contraceptive steroids on development or growth, 69
Proliferative phase premature exposure to progesterone, pituitary, ovarian and endometrial effects, 177
Proposed standard for laboratories involved in development of hCG vaccines, 627
Prostaglandin analogue,
 9-deoxy-16,16-dimethyl-9-methylene PGE₂, 51
 16,16-dimethyl-trans-Δ²PGE₁ methyl ester, 51, 339
 15-methyl PGE_{2α} methyl ester, 51
 16-phenoxy-ω-17,18,19,20-tetranor PGE₂ methyl sulfonylamide, 51
 (15S)15-methyl PGF_{2α} methyl ester, 141
Prostaglandin analogues, comparison for preoperative dilatation of cervix in late first trimester abortion, 51
Protein pattern of cauda fluid, effect of gossypol on epididymis (rat), 391
Quetelet's index,
 effect of ethinyl estradiol + 1-norgestrel, 591
 effect of norethisterone enanthate, 591
Release rates of levonorgestrel, capsules, homogeneous rods and covered rods, 483
Removals,
 levonorgestrel-releasing capsules, 473
 Nova-T, 473
 randomised comparative evaluation of Cu-IUDs, 75
Reproductive organ weights,
 effect of cadmium (rat), 521
 effect of cadmium + zinc (rat), 521
Reproductive tissues, effect of testosterone + estradiol implant (monkey), 363
Risk of pregnancy, missed oral contraceptive pills, 531
RMI 12,936 (17β-hydroxy-7α-methyl-5-androstene-3-one)
(15S)15-methyl PGF_{2α} free acid and methyl ester, extraction from plasma, purification and quantitation, 141
(15S)15-methyl PGF_{2α} level in plasma, polymeric controlled release vaginal delivery system, 141
(15S)15-methyl PGF_{2α} methyl ester, polymeric controlled release vaginal delivery system for menses induction and second trimester pregnancy termination, 141
Saf-T-Coil, effect on plasminogen activator activity in uterine tissue, 131
Second trimester pregnancy termination, polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF_{2α} methyl ester, 141

CONTRACEPTION

- Semen characteristics, effect of testosterone + estradiol implant (monkey), 383
Serum iron level,
 effect of ethynodiol + levonorgestrel in anemic women, 311
 effect of ethynodiol + levonorgestrel with ferrous fumarate in
 anemic women, 311
 effects of IUDs in anemic women, 311
Sex hormone binding globulin,
 effect of ethynodiol + desogestrel monophasic, 577
 effect of ethynodiol + desogestrel sequential, 577
 effect of ethynodiol + levonorgestrel triphasic, 577
Side effects,
 comparison of different prostaglandin analogues and laminaria for preoperative
 cervical dilatation in late first trimester abortion, 51
 comparison of ethynodiol + levonorgestrel monophasic and triphasic versions,
 439
 comparison of mestranol + norethindrone and ethynodiol + norethindrone, 453
 danazol compared with ethynodiol + norgestrel when used for postcoital
 contraception, 39
 effect of vitamin supplementation during oral contraceptive use, 465
 injectable medroxyprogesterone acetate, 161
 levonorgestrel-releasing capsules, 473
 Nova-T, 473
 pre-operative 16,16-dimethyl-trans- Δ^2 PGE₁ methyl ester, 339
Sodium concentration, effect of gossypol on epididymis (rat), 391
Somatic tissue responses, effect of testosterone + estradiol implant (monkey), 363
Sperm concentration, effect of gossypol on epididymis (rat), 391
Sperm motility
 effect of gossypol, 571
 effect of gossypol on epididymis (rat), 391
Sperm population,
 effect of cadmium (rat), 521
 effect of cadmium + zinc (rat), 521
Sperm production, effect of testosterone + estradiol implant (monkey), 347
Spinnbarkeit, normal menstruating women, 329
Stability of solutions, assessment for D-trp⁶-pro⁹-NET-LHRH, 195
Steroids, effect on testosterone synthesis in testis (dog), 431

CONTRACEPTION

- Subcellular distribution, estradiol and estrone in endometrium and myometrium during menstrual cycle, 409
- Subdermal implant,
- capsules containing levonorgestrel, 123, 281
 - capsules releasing levonorgestrel, 483
 - covered rods containing levonorgestrel, 123
 - covered rods releasing levonorgestrel, 483
 - homogeneous rods releasing levonorgestrel, 483
 - levonorgestrel-releasing capsules, 473
- Subdermal polydimethylsiloxane implant, testosterone + estradiol (monkey), 347, 363, 383
- TCu 200, effect on clinical chemistry, 281
- T Cu 220,
- effect of serum ferritin and other hematological parameters, 289
 - predictive value of serum ferritin in anemia development after insertion, 289
- TCu-220C,
- effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
 - randomized comparative evaluation on Cu-IUDs, 75
- Termination rates, randomised comparative evaluation of Cu-IUDs, 75
- Terminations,
- comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
 - effect of vitamin supplementation during oral contraceptive use, 465
- Testis, inhibition of testosterone synthesis by steroids (dog), 431
- Testis function, effect of testosterone + estradiol implant (monkey), 347
- Testosterone + estradiol,
- contraceptive efficacy (monkey), 383
 - effect on testis function (monkey), 347
 - somatic tissue responses (monkey), 363
- Testosterone blood production rate, effect of testosterone + estradiol implant (monkey), 347
- Testosterone level,
- effect of cadmium (rat), 521
 - effect of cadmium + zinc (rat), 521
 - effect of ethinylestradiol + desogestrel monophasic, 577
 - effect of ethinylestradiol + desogestrel sequential, 577
 - effect of ethinylestradiol + levonorgestrel triphasic, 577

CONTRACEPTION

- effect of subdermal implant capsules containing levonorgestrel, 281
- effect of TCu 200, 281
- effect of testosterone + estradiol implant (monkey), 347
- testicular production after testosterone + estradiol implant (monkey), 347
- Testosterone metabolic clearance rate, effect of testosterone + estradiol implant (monkey), 347
- Testosterone synthesis inhibition in testis (dog), 431
- Thyroid stimulating hormone level,
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Thyroid weight,
 - effect of lithosperm (chick), 639
 - effect of lithosperm and propylthiouracil (chick), 639
- Thyroidal ^{32}P uptake,
 - effect of lithosperm (chick), 639
 - effect of lithosperm and propylthiouracil (chick), 639
 - effect of lithosperm and thyroid-stimulating hormone (chick), 639
- Thyroxine level,
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Time of use and corrosion, MLCu250 and MLCu375 IUDs, 85
- Total urinary estrogens, determination in morning urine samples from normally menstruating women, 329
- Toxicological studies, zoapatic aqueous crude extract (rat, dog), 255
- Traditional remedy from Mexico, zoapatic, 211
- Triglycerides level,
 - effect of injectable medroxyprogesterone acetate, 161
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Triiodothyronine level,
 - effect of subdermal implant capsules containing levonorgestrel, 281
 - effect of TCu 200, 281
- Triphasic ethinyl oestradiol + levonorgestrel, comparison to monophasic version on acceptability, 439
- Urine samples collected in the morning from normally menstruating women, determination of total urinary estrogens, 329

CONTRACEPTION

- Use-effectiveness, comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
- Uterine contractility,
effect of hexanic extract of zoapatic aqueous crude extract (rat, guinea pig), 267
effect of kauradienoic acid (rat, guinea pig), 267
effect of zoapatic aqueous crude extract (rat, guinea pig, dog), 267
- Uterine contractions, increase associated with aqueous plant extract of zoapatic, 211
- Uterine response,
dialysed extract of zoapatic crude extract (guinea pig), 239
oxytocin (guinea pig), 239
- Uterine tissue, changes of plasminogen activator activity induced by IUDs, 131
- Uterotonic potency, various Montanoa species, 227
- Uterotonic potency of several specimens of zoapatic (guinea pig), 239
- Uterotonic potency of wild and cultivated specimens of zoapatic (guinea pig), 239
- Uterotonic properties, zoapatic aqueous crude extract (guinea pig), 239
- Uterotrophic/estrogenic activity, effect of RMI 12,936 (rat), 95
- Vacuum aspiration, IPAS Modified Gynecologic Syringe compared with electric pump and standard hand pump, 63
- Vaginal administration of abortifacient, polymeric controlled release delivery system containing (15S)15-methyl PGF₂_α methyl ester, 141
- Vaginal colonization of E. Coli,
relation to contraceptive methods, 497
significantly associated factors, 497
- Vaginal contraceptive, gossypol acetic acid gel, 571
- Vaginal device, releasing progesterone, 177
- Vitamin supplementation, effect on oral contraceptive side effects and discontinuation, 465
- Vomiting, danazol compared with ethinyloestradiol + norgestrel when used for postcoital contraception, 39
- Withdrawal bleeding, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Zinc, effect on cadmium-induced sterility (rat), 521
- Zoapatic (Montanoa tomentosa (Cerv.) s.s.p. tomentosa (Funk.)),
a traditional remedy from Mexico, 211
aqueous plant extract associated with increase in uterine contractions, 211
biological and uterotonic properties of aqueous plant extract (guinea pig), 239
biological observations, 211

CONTRACEPTION

- botanical and ecological determinants, 227
- clinical observations, 211
- effect of hexanic extract (kauradienoic acid) upon uterine contractility (rat, guinea pig, dog), 267
- history, 211
- isolation of active principle(s), 211
- toxicological and clinical studies of aqueous crude extract (rat, dog), 255
- Zoapatle aqueous crude extract,
 - effect on uterine contractility (rat, guinea pig, dog), 267
 - effect on uterine strips of different animal species, 239

